Making Myeloma Treatment Easier: Practical Use of On-Body Delivery
Jointly provided by

Support for this activity has been provided through an educational grant from Sanofi.
Release date: 10/16/2026
Expiration date: 10/16/2027
Estimated time to complete: 1.0 hour
IMPORTANT NOTE: This educational course is not accredited for CME/CE credit.
Overview
Multiple myeloma is increasingly managed as a chronic disease, with patients receiving treatment over many years and across multiple lines of therapy. This can create substantial treatment and logistical burdens, including frequent clinic visits, travel, and time away from daily life. Emerging delivery approaches, such as on-body administration of monoclonal antibodies, may offer opportunities to reduce this burden while maintaining effective disease control.
This webinar will explore the clinical evidence and practical considerations for incorporating on-body administration strategies into multiple myeloma care.
Faculty
Sikander Ailawadhi, MD
Professor of Medicine
Mayo Clinic
Jacksonville, Florida
Caitlin Flott, APRN, MSN
Family Nurse Practitioner
Mayo Clinic
Jacksonville, Florida
Target Audience
This activity has been designed to meet the educational needs of community hematology-oncology health care providers (HCPs) involved in the management of multiple myeloma patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe key contributors to treatment burden in multiple myeloma
- Explain the rationale for efficient administration approaches in newly diagnosed and relapsed/refractory multiple myeloma
- Apply practical strategies for implementing on-body administration in clinical practice, including workflow, patient counseling, and care team coordination
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Multiple Myeloma Research Foundation, RedMedEd, and Sanofi do not recommend the use of any agent outside the labeled indications.
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the Multiple Myeloma Research Foundation, RedMedEd, or Sanofi. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information
For questions related to this activity, please contact RedMedEd at 610.251.6841 or education@redmeded.com.
Privacy
This website is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. The information you provide on this site may be used to contact you about other relevant educational activities. RedMedEd will not knowingly share any personally identifiable information. For more information, contact education@redmeded.com.
Copyright
© 2026. This program is held as copyrighted by the Multiple Myeloma Research Foundation and RedMedEd. Through this notice, the Multiple Myeloma Research Foundation and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.